Targacept is the leading CNS-focused biopharmaceutical company with an extensive portfolio of candidates for first-in-class therapies

Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics(TM), a new class of drugs for the treatment of multiple diseases and disorders of the central nervous system. Our NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity.

We currently have a robust clinical-stage product pipeline and multiple preclinical product candidates. Our most advanced product candidates are in development as treatments for Alzheimer's disease and cognitive dysfunction in schizophrenia, depression and anxiety disorders, and pain.

Targacept is located in Winston-Salem, North Carolina.

 

A proud member of BIO

The North Carolina Biosciences Organization

Neurotechnology Industry Organization

Targacept Named 10th Overall in Best Places to Work Survey
On May 29, 2008, The Scientist, magazine of the life sciences, listed Targacept among the "Best Places to Work in Industry" in its 6th annual survey.
Learn more.

 

Candidates in Pipeline
Targacept has several product candidates in clinical development.
View our pipeline to learn more.
Targeting NNRs
Watch the animation to find out how our drugs work in the nervous system.
  
   
  
Latest News
August 05, 2008
July 21, 2008
June 25, 2008
June 10, 2008
©2008 Targacept, Inc. Terms of Use Directions Contact Site Map  Go